From a longevity medicine perspective, the combination of meaningful weight reduction, improved glycemic control, reduced hepatic fat, and potential cardiovascular benefit represents a multi-pathway intervention on metabolic aging
These areas have been selected based on clinical studies demonstrating adequate subcutaneous tissue depth, consistent absorption profiles, and patient tolerability
Key finding: Vagal afferent signaling and nodose ganglion GLP-1 receptor activation mediate nausea
5.8%), constipation (18.0%, 15.7% vs
Retatrutide is an investigational compound and is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority
The aromatic ring of Phe22 on the peptide engages in direct pi-pi stacking with Phe33 of the GCGR extracellular domain (ECD)